Research article

Promoter Hypermethylation-mediated Inactivation of LRRC4 in Gliomas

Zuping Zhang^1,2 , Dan Li¹ , Minghua Wu¹ , Bo Xiang¹ , Li Wang¹ , Ming Zhou¹ , Pan Chen¹ , Xiaoling Li¹ , Shourong Shen³ and Guiyuan Li¹

¹  Cancer Research Institute, Central South University, Changsha 410078, Hunan, PR China

²  Department of Parasitology, Central South University, Changsha 410078, Hunan, PR China

³  The Third Affiliated Hospital of Xiang Ya School of Medicine, Central South University, Changsha 410078, Hunan, PR China

author email corresponding author email

BMC Molecular Biology 2008, 9:99doi:10.1186/1471-2199-9-99

Published:	3 November 2008

Abstract

Background

Leucine-rich repeat C4 protein (LRRC4) is a new member of the leucine-rich repeat (LRR) superfamily. It is not only a brain-specific gene but also a novel candidate for tumor suppression. LRRC4 inactivation is commonly found in glioma cell lines and primary glioma biopsies. However, little is known about the mechanism controlling LRRC4 expression. In a previous study, we did not find any genetic alteration in LRRC4 in primary glioma, which led us to explore an alternative mechanism underlying this phenomenon.

Methods

In the present paper, we cloned the LRRC4 promoter with characteristics of a CpG island by luciferase reporter assay. Then, the CpG methylation status around the LRRC4 promoter region in glioma cell lines and primary gliomas was examined by methylation-specific PCR and bisulfite DNA sequencing. In order to demonstrate a functional association between LRRC4 promoter methylation and its gene inactivation, we performed DNA demethylation analysis with two human glioma cell lines using methylation-specific PCR and RT-PCR.

Results

The sequence spanning positions -835 to -293 relative to the translation start site was identified as the LRRC4 promoter; this sequence is a TATA- and CAAT- less, high GC content region. It was found that LRRC4 promoter activity is strongly suppressed after treatment with SssI methylase in vitro. Furthermore, LRRC4 promoter methylation was observed by methylation-specific PCR in two glioma cell lines and all 30 primary glioma specimens, but not in normal brain tissue. Bisulfite DNA sequencing showed that most of the CpG sites were located around the LRRC4 promoter methylated in glioma cells and tissues, but not in normal brain tissue. In addition, the methylase inhibitor 5-Aza-2'-deoxycytidine could induce LRRC4 mRNA expression and LRRC4 promoter partial demethylation in SF126 and SF767 glioma cells.

Conclusion

Methylation-mediated inactivation of LRRC4 is a frequent and glioma-specific event, and it may be a potential biomarker for diagnosis or prognosis, or serve as a therapeutic target.